Hepatoprotective effects of geniposide in a rat model of nonalcoholic steatohepatitis

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 4, 2011, Pages 587-593

  Ma, Taotao ^a   Huang, Cheng ^a   Zong, Guojun ^b   Zha, Dajun ^b   Meng, Xiaoming ^c   Li, Jun ^a   Tang, Wenjian ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b Hefei XinFeng Co Ltd   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Geniposide; Lipid peroxidation; Non alcoholic steatohepatitis (NASH); Rats

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CYTOCHROME P450 2E1; FATTY ACID; GENIPOSIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; FATTY ACID BLOOD LEVEL; FIBROGENESIS; INSULIN BLOOD LEVEL; LIPID DIET; LIVER HISTOLOGY; LIVER PROTECTION; LIVER WEIGHT; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ALANINE TRANSAMINASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ASPARTATE AMINOTRANSFERASES; CYTOCHROME P-450 CYP2E1; DIETARY FATS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FATTY LIVER; INSULIN; IRIDOIDS; LIPID METABOLISM; MALE; MALONDIALDEHYDE; PPAR ALPHA; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79952715994     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01256.x     Document Type: Article

References (34)

1. Bruce KD et al. Maternal high-fat feeding primes steatohepatitis in adult mice offspring, involving mitochondrial dysfunction and altered lipogenesis gene expression. Hepatology 2009; 50: 1796-1808.
2. Das K, Kar P. Non-alcoholic steatohepatitis. J Assoc Physicians India 2005; 53: 195-199. (Pubitemid 41280100)
3. Page JM, Harrison SA. NASH and HCC. Clin Liver Dis 2009; 13: 631-647.
4. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-S112.
5. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001; 21: 27-41. (Pubitemid 32240484)
6. Huang C et al. Potential protective effects of a traditional Chinese herb, Litsea coreana Levl., on liver fibrosis in rats. J Pharm Pharmacol 2010; 62: 223-230.
7. Koo HJ et al. Antiinflammatory effects of genipin, an active principle of gardenia. Eur J Pharmacol 2004; 495: 201-208.
8. Koo HJ et al. Geniposide, an anti-angiogenic compound from the fruits of Gardenia jasminoides. Planta Med 2004; 70: 467-469.
9. Zhang CY et al. Genipin inhibits UCP2-mediated proton leak and acutely reverses obesity- and high glucose-induced beta cell dysfunction in isolated pancreatic islets. Cell Metab 2006; 3: 417-427.
10. Inao M et al. Japanese herbal medicine Inchin-ko-to as a therapeutic drug for liver fibrosis. J Hepatol 2004; 41: 584-591. (Pubitemid 39297793)
11. Wu SY et al. Effect of geniposide, a hypoglycemic glucoside, on hepatic regulating enzymes in diabetic mice induced by a high-fat diet and streptozotocin. Acta Pharmacol Sin 2009; 30: 202-208.
12. Zou Y et al. High-fat emulsion-induced rat model of nonalcoholic steatohepatitis. Life Sci 2006; 79: 1100-1107. (Pubitemid 44102717)
13. Brunt EM et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474. (Pubitemid 29420675)
14. Musso G et al. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev 2009; 11: 430-445.
15. Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2002; 17(Suppl.): S186-S190. (Pubitemid 34539308)
16. Angulo P, Lindor KD. Treatment of non-alcoholic steatohepatitis. Best Pract Res Clin Gastroenterol 2002; 16: 797-810.
17. Marchesini G et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-1850. (Pubitemid 33641605)
18. Puri P et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007; 46: 1081-1090. (Pubitemid 350144772)
19. Chalasani N et al. Metabolic and anthropometric evaluation of insulin resistance in nondiabetic patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003; 98: 1849-1855. (Pubitemid 36959169)
20. Feldstein AE et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004; 40: 185-194. (Pubitemid 38868937)
21. Perez-Carreras M et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003; 38: 999-1007. (Pubitemid 37221683)
22. Jarrar MH et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 27: 412-421.
23. Svegliati-Baroni G et al. A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferatoractivated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Am J Pathol 2006; 169: 846-860. (Pubitemid 44411952)
24. Musso G et al. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2005; 100: 2438-2446.
25. Hui JM et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004; 40: 46-54. (Pubitemid 38868922)
26. Masaki T et al. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology 2004; 40: 177-184. (Pubitemid 38868936)
27. Ip E et al. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 2003; 38: 123-132. (Pubitemid 36775803)
28. Chou CJ et al. WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. J Biol Chem 2002; 277: 24484-24489. (Pubitemid 34951973)
29. Hill MR et al. Effect of peroxisome proliferator-activated receptor alpha activators on tumor necrosis factor expression in mice during endotoxemia. Infect Immun 1999; 67: 3488-3493. (Pubitemid 29291520)
30. Anderson SP et al. Delayed liver regeneration in peroxisome proliferator-activated receptor-alpha-null mice. Hepatology 2002; 36: 544-554. (Pubitemid 34977164)
31. Brunt EM. Alcoholic and nonalcoholic steatohepatitis. Clin Liver Dis 2002; 6: 399-420, vii.
32. Yoshioka S et al. Effects of Eriobotrya japonica seed extract on oxidative stress in rats with non-alcoholic steatohepatitis. J Pharm Pharmacol 2010; 62: 241-246.
33. Uzun MA et al. Effects of N-acetylcysteine on regeneration following partial hepatectomy in rats with nonalcoholic fatty liver disease. Surg Today 2009; 39: 592-597.
34. Leclercq IA et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000; 105: 1067-1075. (Pubitemid 30217691)